登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市肺科医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07874581,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically confirmed small cell lung cancer (SCLC);
入选标准第 3 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
入选标准第 6 条
History of drug abuse, chronic alcohol abuse, AIDS, or HIV infection;
排除标准第 4 条
History of malignancy within the previous 3 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ with an expected survival of >3 years, such as breast cancer in situ, oral carcinoma in situ, or cervical carcinoma in situ;
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07874581,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed informed consent form (ICF); Age ≥18 years at the time of signing informed consent; Histologically confirmed small cell lung cancer (SCLC); Extensive-stage SCLC (ES-SCLC) with disease progression or recurrence after prior treatment; At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the investigator; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Adequate organ and bone marrow function. Women of childbearing potential must use highly effective contraception from screening until 3 months after discontinuation of study treatment and must have a negative pregnancy test (serum or urine) within 7 days before enrollment. Male participants must agree to use appropriate contraception from screening until 3 months after discontinuation of study treatment or have undergone surgical sterilization; No anticancer therapy was received within the specified washout period before the first dose of study treatment; Estimated life expectancy ≥12 weeks.排除标准:Exclusion Criteria:
Known hypersensitivity to becotatug vedotin; History of another active malignancy requiring treatment or history of allogeneic organ transplantation; Major surgery (excluding diagnostic biopsy) within 4 weeks before the first dose of study treatment; History of drug abuse, chronic alcohol abuse, AIDS, or HIV infection; Active autoimmune disease or history of autoimmune disease with potential risk of recurrence; Current systemic corticosteroid therapy (e.g., prednisone equivalent >10 mg/day) or use of any other immunosuppressive therapy within 14 days before the first dose of study treatment; Interstitial lung disease (ILD), or previous ILD requiring corticosteroid treatment; History of idiopathic pulmonary fibrosis (IPF), drug-induced pneumonitis, organizing pneumonia (including bronchiolitis obliterans organizing pneumonia), or idiopathic pneumonia; Receipt of live vaccines within 28 days before the first dose of study treatment; Any disease or condition that may contraindicate anticancer therapy, including but not limited to active infection, myocardial infarction within 6 months, symptomatic cardiac disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmia), or ongoing immunosuppressive therapy; Pregnancy or breastfeeding; or male or female participants unwilling to use appropriate contraception when pregnancy is possible; Evidence of hereditary bleeding disorders or coagulation abnormalities; History of malignancy within the previous 3 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ with an expected survival of >3 years, such as breast cancer in situ, oral carcinoma in situ, or cervical carcinoma in situ; Any other medical history, disease, treatment, or laboratory abnormality that may interfere with study results, prevent full participation in the study, or make the participant unsuitable for enrollment as judged by the investigator.
引自 ClinicalTrials.gov, NCT07874581, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07874581,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。